Keunchil Park

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

115h-index74.6kcitations966works22.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(554), Lung Cancer Research Studies(242), Lung Cancer Diagnosis and Treatment(198), Colorectal Cancer Treatments and Studies(149), Cancer Genomics and Diagnostics(128)

Publications910 total

Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study
Targeted Oncology·2025Open Access
Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study
Journal of Clinical Oncology·2025· 12 citedOpen Access
Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC
Lung Cancer·2025
Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer
Lung Cancer·2025· 4 citedOpen Access
Selpercatinib in <i>RET</i> Fusion–Positive Non–Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial
Journal of Clinical Oncology·2025· 13 citedOpen Access
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
Nature Reviews Clinical Oncology·2025· 37 cited
Patient-Reported Outcomes and Time to Symptomatic Progression from Papillon: Amivantamab Plus Chemotherapy vs Chemotherapy as First-Line Treatment of Egfr Exon 20 Insertion-Mutated Advanced Nsclc
SSRN Electronic Journal·2025Open Access
RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC
Journal of Thoracic Oncology·2024· 13 cited
Intracranial outcomes of 1L selpercatinib in advanced <i>RET</i> fusion-positive NSCLC: LIBRETTO-431 study.
Journal of Clinical Oncology·2024
Plain language summary of PAPILLON: amivantamab plus chemotherapy in untreated <i>EGFR</i> -mutated non-small-cell lung cancer
Future Oncology·2024· 3 citedOpen Access
The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group
Cancer Research and Treatment·2024Open Access
CNS Protective Effect of Selpercatinib in First-Line <i>RET</i> Fusion-Positive Advanced Non–Small Cell Lung Cancer
Journal of Clinical Oncology·2024· 11 citedOpen Access
Intracranial outcomes of 1L selpercatinib in advanced <i>RET</i> fusion-positive NSCLC: LIBRETTO-431 study.
Journal of Clinical Oncology·2024· 2 cited
A phase II, open-label, combination therapy of durvalumab and ceralasertib in relapsed and refractory small cell lung cancer (SUKSES-N4).
Journal of Clinical Oncology·2024· 5 cited
A phase II, open-label, efficacy and safety of olaparib with bevacizumab (SUKSES-B2) in biomarker matched relapsed or refractory small cell lung cancer.
Journal of Clinical Oncology·2024
Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non–Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 Trial
Cancer Research and Treatment·2024· 3 citedOpen Access
Abstract 5162: Tumor transcriptional identity as a key predictor of clinical outcome in EGFR-Mutant non-small cell lung cancer
Cancer Research·2024
Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer
EBioMedicine·2024· 36 citedOpen Access
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
Nature Medicine·2024· 104 citedOpen Access
Predicting disease recurrence in limited disease small cell lung cancer using cell-free DNA-based mutation and fragmentome analyses
Translational Lung Cancer Research·2024· 6 citedOpen Access
page 1 of 46Next →

Frequent Co-authors

Myung‐Ju Ahn(12), Jin Seok Ahn(11), Se‐Hoon Lee(10), Sang‐We Kim(9), Filippo de Marinis(8), Fabrice Barlési(7), Martin Reck(7), Jong‐Mu Sun(7), James Chih‐Hsin Yang(7), Joachim von Pawel(6), Luis Paz‐Ares(6), Ki Hyeong Lee(6), Johan Vansteenkiste(5), Kenneth J. O’Byrne(5), Yoon‐La Choi(5), Byoung Chul Cho(5), Makoto Nishio(5), Dariusz M. Kowalski(4), Jong-Seok Lee(4), David R. Gandara(4)